Baseline sea-level characteristics
| Placebo | Losartan | P value | ACE genotype and pair no. | ||||||
| Female pairs | Male pairs | ||||||||
| Age (years) | 38.6±18.5 | 40.4±18.0 | 0.83 | 1 | ID | ID | 4 | II | II |
| Body mass (kg) | 74.1±11.5 | 66.7±13.3 | 0.71 | 2 | ID | ID | 5 | II | II |
| Height (cm) | 172.6±8.4 | 176.4±8.9 | 0.83 | 3 | ID | ID | 6 | ID | ID |
| GFR (mL/min/1.73 m2) | 88.0±15.2 | 90.8±15.8 | 0.69 | 7 | ID | ID | |||
| eGFR (mL/min/1.73 m2) | 87.8±15.3 | 90.8±15.9 | 0.68 | 8 | ID | ID | |||
| Creatinine (μmol/L)* | 84.5±24.0 | 81.0±31.0 | 0.58 | 9 | DD | ID | |||
| 10 | DD | DD | |||||||
Baseline results were obtained at sea level and prior to the administration of placebo and losartan. Results for continuous variables are reported as mean±SD unless indicated by *, where values are reported as median ± IQR. ACE genotypes are presented as allelic variations (II, ID and DD). Significance was set to p value <0.05. No significant differences between groups were evident at baseline sea level. Subjects were equally matched for sex (men and women). All genotypes were observed and 90% matched.
eGFR, estimated glomerular filtration rate (calculated using the MDRD study equation); GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.